Clinical Trial Detail

NCT ID NCT03631706
Title M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors EMD Serono Research & Development Institute, Inc.
Indications

lung non-small cell carcinoma

Therapies

M7824

Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST